Determinants of vancomycin use in adult intensive care units in 41 United States hospitals

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1119-1125

  Fridkin, Scott K ^a,b   Edwards, Jonathan R ^a   Pichette, Sarah C ^a   Pryor, Erica R ^a   McGowan Jr , John E ^a   Tenover, Fred C ^a   Culver, David H ^a   Gaynes, Robert P ^a  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CATHETER INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIVARIATE ANALYSIS; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES; URINARY TRACT INFECTION; VENTILATOR;

EID: 0032938912     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514752     Document Type: Article

References (44)

1. 1. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975 1991. Infect Control Hosp Epidemiol 1992;13:582-6.
2. 2. Coronado VG, Edwards JR, Culver DH, Gaynes RP, National Nosocomial Infections Surveillance System. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States, Infect Control Hosp Epidemiol 1995;16:71-5.
3. 3. Archibald L, Phillips L, McGowan JE Jr, Monnet D, Tenover FC, Gaynes RP. Antimicrobial resistance in hospitals and outpatients in the United States: the increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
4. 4. Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am 1996;11:479-96.
5. 5. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA 1993;269:598-602.
6. 6. Rifenburg RP, Paladino JA, Hanson SC, Tuttle JA, Schentag JJ. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Hosp Pharm 1996;53:2054-62.
7. 7. Kirst HA, Thompson DG, Nicas TJ. Historical yearly usage of vancomycin. Antimicroh Agents Chemother 1998;42:1303-4.
8. 8. Centers for Disease Control and Prevention, Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
9. 9. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus fuecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-53.
10. 10. Morris JGJ, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9.
11. 11. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
12. 12. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-6.
13. 13. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5.
14. 14. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1996;16:105-13.
15. 15. Hamilton CD, Drew R, Hayward S, Kure J, Janning S. Improving clinician adherence to vancomycin-use guidelines: results of a pharmacist-based strategy at an academic medical center [abstract no 381]. Clin Infect Dis 1997;25:425.
16. 16. Salemi C, Recker L, Morrissey R, Warmington J. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Clinical Performance and Quality Health Care 1998;1: 12-6.
17. 17. Petrofsky MV, Dicker RC. Vancomycin utilization project based on the HICPAC guidelines in thirteen northeastern states [abstract no S10]. Infect Control Hosp Epidemiol 1997;18:P33.
18. 18. Johnson SV, Hoey LL, Vance-Bryan K. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy 1995;15:579-85.
19. 19. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol 1996;17:356-9.
20. 20. Watanakunakom C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767-9.
21. 21. Singer MV, Haft R, Barlam T, Aronson M, Shafer A, Sands KE. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998; 19:248-53.
22. 22. Klem C, Dasta JF. Efforts of pharmacy to reduce antibiotic resistance. New Horizons 1996;4:377-84.
23. 23. Frank MO, Batteiger BE, Sorensen SJ, et al. Decrease in expenditures and selected nosocomial infections following implementation of antimicrobial-prescribing improvement program. Clinical Performance and Quality Health Care 1997;5:180-8.
24. 24. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-9.
25. 25. McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994; 15:478-83.
26. 26. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 1996;275:234-40.
27. 27. Shlaes DM, Gerding DN, John JK, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the preventions of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275-91.
28. 28. Fridkin SK, Edwards JR, Pryor ER, et al. Impact of clinical practice guidelines on vancomycin use in adult intensive care units at U.S. hospitals [abstract no 17]. Presented at the 8th Annual Meeting of the Society for Healthcare Epidemiology of America (5-7 April, 1998; Orlando, Fl).
29. 29. Garner JS, Jarvis WR, Emori G, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-40.
30. 30. Emori G, Culver DH, Horan TC, et al. National Nosocomial Infections Surveillance (NNIS); description of surveillance methods. Am J Infect Control 1991;19:19-35.
31. 31. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-46.
32. 32. Jarvis WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect Control Hosp Epidemiol 1996;17:490-5.
33. 33. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996;124:884-90.
34. 34. Hospital Infections Program, CDC. National Nosocomial Infections Surveillance (NNIS) semiannual report. May 1995. Am J Infect Control 1996;24:380-8.
35. 35. Pearson ML, The Hospital Infection Control Practices Advisory Committee. Guideline for prevention of intravascular device related infections. Part I. Intravascular device-related infections: an overview. Am J Infect Control 1996;24:262-77.
36. 36. Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices. Am J Infect Control 1996;24:24-31.
37. 37. Guglielmo BJ. Practical strategies for the appropriate use of antimicrobials, Pharm World Sci 1995;17:96-102.
38. 38. Avorn J, Harvey K, Soumerai SB, Herxheimer A, Plumridge R, Bardelay G. Information and education as determinants of antibiotic use: report of Task Force 5. Rev Infect Dis 1987;9:S286-96.
39. 39. Monnet D, Biddle JW, Edwards JR, et al. Evidence of interhospital transmission of extended-spectrum β-lactam-resistant Klebsiella pneumoniae in the United States, 1986-1993. Infect Control Hosp Epidemiol 1997;18:492-8.
40. 40. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-85.
41. 41. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998;338:232-8.
42. 42. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020-5.
43. 43. Rice LB, Eckstein EC, DeVente J, Shlaes DM, Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118-24.
44. 44. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-6.